Subscribe (Free) to
Daily or Weekly Newsletters
Post a Job

Featured Jobs

Retirement Relationship Manager

MAP Retirement
(Remote)

MAP Retirement logo

Temporary Document Specialist

BPAS
(Utica NY)

BPAS logo

Regional Vice President, Sales

MAP Retirement
(Remote)

MAP Retirement logo

Defined Benefit Plan Consultant/Actuarial Analyst

Sentinel Group
(Remote / Everett MA)

Sentinel Group logo

Plan Administrator, Defined Benefit & Cash Balance

The Pension Source
(Remote / Stuart FL / NY / TX / Hybrid)

The Pension Source logo

Retirement Plan Consultant

MAP Retirement
(Remote)

MAP Retirement logo

Strategic Retirement Plan Consultant

Retirement Plan Consultants
(Urbandale IA / Des Moines IA)

Retirement Plan Consultants logo

Data Administrator II

DWC - The 401(k) Experts
(Remote)

DWC - The 401(k) Experts logo

Retirement Plan Consultant

Sentinel Group
(Remote / Everett MA)

Sentinel Group logo

Plan Consultant - DB/CB

MAP Retirement
(Remote)

MAP Retirement logo

Retirement Plan Administrator

Pattison Pension
(Albuquerque NM / Hybrid)

Pattison Pension logo

View More Employee Benefits Jobs

Free Newsletters

“BenefitsLink continues to be the most valuable resource we have at the firm.”

-- An attorney subscriber

Mobile app icon
LinkedIn icon     Twitter icon     Facebook icon

Text of CMS Final Regs Requiring Drug Pricing Transparency for Medicare and Medicaid Programs
Centers for Medicare & Medicaid Services [CMS], U.S. Department of Health and Human Services [HHS] Link to more items from this source
[Official Guidance]
May 8, 2019
102 pages. "This final rule [amends] regulations for the Medicare Parts A, B, C and D programs, as well as the Medicaid program, to require direct-to-consumer (DTC) television advertisements of prescription drugs and biological products for which payment is available through or under Medicare or Medicaid to include the Wholesale Acquisition Cost (WAC or list price) of that drug or biological product. This rule is intended to improve the efficient administration of the Medicare and Medicaid programs by ensuring that beneficiaries are provided with relevant information about the costs of prescription drugs and biological products so they can make informed decisions that minimize their out-of-pocket (OOP) costs and expenditures borne by Medicare and Medicaid, both of which are significant problems." [Editor's note: Includes over 80 pages of summary, analysis and response to the 147 comments received on the proposed regs. Also available: CMS Drug Pricing Transparency Fact Sheet.]

MORE >>

Please click here to report this link if it is broken (for example, if you see a "404 File Not Found" error message after you click on the linked news item's title).
An important word about authorship: BenefitsLink® created this link to the news item, but we are not the news item's author (unless expressly shown above).